Advances in medical diagnosis, treatment, and care (AMDTC) book series,
Год журнала:
2024,
Номер
unknown, С. 1 - 28
Опубликована: Дек. 17, 2024
The
clinical
translation
of
spatial
transcriptomics
represents
cancer
diagnosis
and
therapy
based
on
the
role
heterogeneity
cancer-associated
fibroblasts
(CAFs)
within
tumor
microenvironment
(TME).
Recent
developments
in
have
enabled
a
detailed
characterization
organization
cellular
interactions
tumors.
data
integration,
multi-omics
approaches,
along
with
developing
standardized
protocols
is
essential
for
effective
translation.
experimental
selection
regimes
factorial
designs
reveals
novel
insights
into
biomarkers
prognostic
value
CAFs.
incorporation
optogenetics
advancements
bio-engineered
gene
circuits,
therapeutics
tissue
engineering
further
underscores
potential
to
refine
patient
stratification
improve
treatment
responsiveness.
By
integrating
workflows,
this
work
aims
advance
personalized
therapies
biology.
Follicular
lymphoma
(FL),
the
second
most
common
subtype
of
non-Hodgkin
lymphoma,
relies
on
interactions
with
immune
elements
in
tumor
microenvironment,
including
T-follicular
helper
cells
and
follicular
dendritic
cells,
for
its
survival
progression.
Despite
initial
responsiveness
to
chemoimmunotherapy,
FL
is
generally
considered
incurable.
Strategies
improve
immune-mediated
control
could
significantly
benefit
this
population,
particularly
as
it
includes
many
elderly
comorbid
patients.
Immune
cell
engagers,
especially
bispecific
antibodies
(BsAbs),
are
crucial
targeting
by
bridging
effector
thereby
triggering
T-cell
activation
cytotoxic
killing.
CD3
×
CD20
BsAbs
have
shown
promise
clinical
development
B-NHL
patients,
structural
variations
affecting
their
target
affinity
potency.
This
review
summarizes
current
trials
relapsed/refractory
FL,
highlighting
approval
some
agents,
role
first-line
treatment
or
combination
therapies,
toxicity
profiles,
future
therapeutic
approach
compared
other
therapies.
eJHaem,
Год журнала:
2024,
Номер
5(6), С. 1173 - 1181
Опубликована: Окт. 10, 2024
Abstract
Background
The
tumor
microenvironment
(TME),
including
infiltrating
T‐cells,
is
thought
to
play
a
major
role
in
the
pathogenesis
and
prognosis
of
follicular
lymphoma
(FL)
may
contribute
its
widely
varied
disease
course.
We
hypothesized
that
programmed
death‐1
inhibition
be
most
effective
untreated,
immunocompetent
FL
patients.
Thus,
we
developed
phase
2
study
evaluate
efficacy
pembrolizumab
as
initial
treatment
for
indolent
B‐cell
lymphoma.
Methods
Adults
with
or
marginal
zone
an
indication
were
eligible.
Patients
received
200
mg
IV
21‐day
cycles
up
18
cycles,
until
progression
unacceptable
toxicity.
Early
response
assessment
was
obtained
after
cycle
3
computed
tomography
(CT),
fluorodeoxyglucose
(FDG)‐positron
emission
tomography‐computed
(PET‐CT)
6
determine
candidacy
continuation
study.
Immunosecretome
profiling
performed
at
baseline
on
day
1.
Results
Nine
patients
enrolled
between
February
2019
April
2021,
eight
(89%)
advanced
stage,
seven
(78%)
intermediate/high
Follicular
Lymphoma
International
Prognostic
Index,
six
(67%)
high‐tumor
burden
by
Groupe
d'Etude
des
Lymphomes
Folliculaires.
best
overall
rate
FDG
PET‐CT
33%
(three
partial
metabolic
responses).
Three
(33%)
had
stable
disease,
three
progressive
(including
one
patient
who
only
follow‐up
CT).
By
CT
four
(44%)
experienced
reduction
target
lesions,
but
all
less
than
responses.
Grade
higher
immune‐related
adverse
events
(IRAEs)
seen
two
(22%)
patients,
both
transaminitis
whom
concurrent
hypophysitis.
Another
grade
1
pneumonitis,
requiring
steroids.
No
associations
immunosecretome
profile
clinical
outcomes
could
detected.
Conclusion
Frontline
associated
limited
responses
clinically
significant
IRAEs.
Alternative
strategies
targeting
TME
should
explored.
Advances in medical diagnosis, treatment, and care (AMDTC) book series,
Год журнала:
2024,
Номер
unknown, С. 1 - 28
Опубликована: Дек. 17, 2024
The
clinical
translation
of
spatial
transcriptomics
represents
cancer
diagnosis
and
therapy
based
on
the
role
heterogeneity
cancer-associated
fibroblasts
(CAFs)
within
tumor
microenvironment
(TME).
Recent
developments
in
have
enabled
a
detailed
characterization
organization
cellular
interactions
tumors.
data
integration,
multi-omics
approaches,
along
with
developing
standardized
protocols
is
essential
for
effective
translation.
experimental
selection
regimes
factorial
designs
reveals
novel
insights
into
biomarkers
prognostic
value
CAFs.
incorporation
optogenetics
advancements
bio-engineered
gene
circuits,
therapeutics
tissue
engineering
further
underscores
potential
to
refine
patient
stratification
improve
treatment
responsiveness.
By
integrating
workflows,
this
work
aims
advance
personalized
therapies
biology.
